Homogeneous Clonal Marrow Stem Cells for cGVHD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic graft-versus-host disease (cGVHD) are ineffective and have significant side effects, and there is a lack of successful therapies using mesenchymal or marrow stem cells.
Innovation Solution
A therapeutic agent utilizing homogeneous clonal marrow stem cells isolated through a subfractionation culturing method, which involves multiple steps of culturing and transferring supernatant to isolate a homogenous population of cells expressing specific cell surface antigens, is administered to patients to inhibit T-cell activity and treat cGVHD symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for cGVHD, then T-cell activity is suppressed, but significant side effects occur and treatment effectiveness is limited
Solution Approach 1:
The patent uses mesenchymal stem cells as an intermediary substance to mediate the immunosuppressive effect. Instead of directly suppressing T-cells with drugs that cause side effects, the mesenchymal stem cells act as a biological mediator that naturally suppresses T-cell activity through cell-to-cell interaction and secretion of immunosuppressive factors, thereby achieving treatment effectiveness while avoiding the harmful side effects of conventional treatments
Solution Approach 2:
The patent employs mesenchymal stem cells that can be cultured in vitro and administered as a temporary therapeutic agent. These cells serve their immunosuppressive function and then are naturally cleared from the body, providing a short-term intervention that avoids long-term toxicity associated with conventional immunosuppressive drugs
2Object-affected harmful factors
If mesenchymal stem cells are used to treat cGVHD, then T-cell suppression is achieved with fewer side effects, but the cells must be precisely isolated and cultured
Solution Approach 1:
The patent segments the complex process of mesenchymal stem cell isolation into distinct steps: first isolating mononuclear cells from bone marrow, then further isolating mesenchymal stem cells from the mononuclear cell population through specific culture conditions. This segmentation simplifies the overall process by breaking it into manageable stages with clear selection criteria at each step
Solution Approach 2:
The patent utilizes the inherent properties of mesenchymal stem cells to enable their own isolation and identification. The cells naturally adhere to culture vessels and differentiate under specific culture conditions, allowing them to self-select and self-identify without requiring complex external sorting mechanisms or markers
3Stability of the object's composition
If homogeneous clonal marrow stem cells are isolated through subfractionation culturing, then cell homogeneity is achieved, but multiple culturing steps are required
Solution Approach 1:
The patent performs preliminary enrichment of mesenchymal stem cells through initial culture steps that select for adherent cells before the final isolation. This preliminary action prepares the cell population in advance, making the subsequent isolation steps more efficient and reducing the total time required to achieve homogeneous clonal populations
Solution Approach 2:
The patent maintains continuous culture of the mesenchymal stem cells through multiple passages, allowing the cells to continuously proliferate and maintain their homogeneous characteristics. This continuous useful action ensures that the cells remain in an active, undifferentiated state throughout the isolation process, reducing the need for repeated starting and stopping that would increase time loss
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively reduces T-cell activity and alleviates symptoms of cGVHD, such as gastrointestinal issues and elevated alkaline phosphatase levels, with no adverse reactions observed, demonstrating the potential for a new, effective treatment for cGVHD.
Implementation Method 1
it is known that there is no change in the activity of karyotypes or telomerases in the MSC when split 50 times
Data Source
AI summary
This present application describes a therapeutic agent for treating acute or chronic graft- versus-host disease using clonal marrow stem cells (cMSCs) as active ingredient.